pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

FDA hiring delays persist despite expectations, and Bavarian Nordic names new CEO

Sep 17, 2026·read at STAT ↗RegulatoryNeutral

The recent discussion about a hiring surge at the U.S. Food and Drug Administration following last year’s DOGE budget cuts has not materialized as expected. Industry observers had anticipated a rapid expansion of staff, but the reality appears more nuanced.

According to the source, bureaucratic hurdles are slowing the hiring process, creating a more complicated picture than the anticipated hiring spree. These delays suggest that administrative and procedural issues are influencing the pace of new appointments.

In separate news, Bavarian Nordic announced the appointment of a new chief executive officer. The leadership change marks a notable development for the company, though further details about the new CEO’s background were not provided.

source

This writeup was produced by pharmadog from original reporting by STAT. The original article may no longer be reachable at its published URL.

Original headline: “STAT+: Pharmalittle: We’re reading about FDA hiring delays, a new Bavarian Nordic CEO, and more”

read at STAT ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoSTAT+: A Sellas immunotherapy study, long delayed, will end in failureSTAT
  • 2h agoSTAT+: A biotech hedge fund births a new immunology companySTAT
  • 4h agoOpinion: What happened to oppositional defiant disorder?STAT
  • 4h agoSTAT+: The FDA’s rebuilding effort is running into a new challengeSTAT
  • 5h agoSTAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing dealSTAT